Reviews/SGLT2 Inhibitors/SGLT2 inhibitors increase the risk of genital mycotic infections
· SG-SF-01 · v2
This claim asks whether SGLT2 inhibitors make fungal genital infections more likely. In the trials here, these infections turned up far more often in patients on the drug than on placebo, across three different molecules [4][5][6]. Large real-world studies that tracked tens of thousands of patients found the same thing, with roughly a one-and-a-half to two-and-a-half times higher rate than comparison drugs [7][11][15]. Pooled safety data in both diabetes [18] and heart failure [10] pointed the same way. Nothing in this corpus pointed the other direction, so the panel treated the direction of the effect as settled and the remaining debate as being about exactly how large it is.
Randomised trials report genital mycotic infections almost exclusively in the SGLT2i arm: ertugliflozin 3.7%-14.1% versus placebo 0%-1.9% [4], empagliflozin 4.0% with none specified for placebo [5], and higher rates with sotagliflozin than placebo [6]. Large active-comparator cohorts quantify the increase as a 2.47-fold adjusted risk versus DPP4 inhibitors [7], a hazard ratio of 1.65 versus GLP-1 receptor agonists in men [11], and a hazard ratio of 1.70 versus DPP4 inhibitors in the super-elderly [15]. Pooled primary-data analyses reproduce the direction: dapagliflozin 5.5% versus placebo 0.6% [18], and empagliflozin raised mycotic genitourinary infections in heart failure [10]. Observational series describe the burden in users without a clean comparator [2][8][17]. The contested point: The evidence does not divide on whether the risk exists, only on its magnitude, which shifts with the comparator and population. Active-comparator cohorts [7][11][15] measure the effect against other active drugs rather than placebo, and the strongest placebo-anchored pooled estimates [3][9] were removed by the study-type filter.
All 20 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from SGLT2 Inhibitors, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Three included observational studies ([2],[8],[17]) report GMI incidence in SGLT2i users but carry no non-SGLT2i comparator, so they establish burden, not relative risk; the comparative claim rests solely on [4],[5],[6],[7],[10],[11],[15],[18].
The largest comparative estimates ([3],[9]) were removed by the study-type filter; surviving cohort estimates ([7],[11],[15]) use active comparators (DPP4, GLP-1RA) rather than placebo, so magnitudes are comparator-dependent and may understate the placebo-relative effect.
Where it remains uncertain. Magnitude is comparator-dependent: surviving cohort estimates use active comparators [7][11][15], while placebo-anchored meta-analyses [3][9] were excluded by study type.
Aleatory
Rates differ by sex, age, BMI and glycaemic control [2], so whether any given patient develops an infection is irreducibly variable.
Epistemic
Surviving comparative estimates use active comparators [7][11][15]; the placebo-anchored magnitude is not directly measured in the included primary studies.
Inferential
[11] measures male external genital infection in a Fournier context; generalising to all genital mycotic infections requires combining it with female and mixed data [4][15].
The load-bearing papers from a corpus of 20, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Randomised placebo-controlled evidence of raised GMI with ertugliflozin in both sexes.
“A higher incidence of genital mycotic infections was observed in male and female patients receiving ertugliflozin (3.7%-14.1%) vs placebo (0%-1.9%) through Week 52.”
Panel auditInternal validity: high · scope of inference: T2DM inadequately controlled on metformin plus sitagliptin, eGFR >=60; ertugliflozin specifically.Key limitations: no inferential test reported for GMI · single SGLT2i agent
RCT showing genital infections confined to the empagliflozin arm.
“Genital infections were reported only with empagliflozin (4.0%).”
Panel auditInternal validity: medium · scope of inference: T2DM inadequately controlled on metformin; empagliflozin short-term.Key limitations: short 12-week duration · no p for genital infections · not mycotic-specific
Large NEJM RCT confirming higher GMI with sotagliflozin vs placebo.
“Diarrhea, genital mycotic infections, volume depletion, and diabetic ketoacidosis were more common with sotagliflozin than with placebo.”
Panel auditInternal validity: high · scope of inference: Type 2 diabetes with CKD and cardiovascular risk; sotagliflozin.Key limitations: no numeric estimate for GMI · trial ended early · dual SGLT1/2 agent
Non-adherent SGLT2i women had genital infections at 9.6% while control women were 2.7-3.1% regardless of adherence, pointing toward higher genital infection with SGLT2i, though the tested p applies to within-group adherence not the drug contrast.
Panel auditInternal validity: low · scope of inference: Post-menopausal T2DM women educated on hygiene practices; conditional on hygiene adherence.Key limitations: hygiene confound · inconsistent n · questionnaire outcome · not mycotic-specific
4 of 20 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Multiple independent RCTs and large real-world cohorts converge on the same direction and effect, meeting the Established bar.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Placebo-anchored magnitude from primary data. Surviving comparative estimates are against active comparators, so the placebo-relative effect size is inferred rather than measured here [7][11][15]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A patient-level pooled analysis of placebo-controlled RCTs reporting genital mycotic infection as a pre-specified outcome.
Open question: What is the placebo-relative magnitude of genital mycotic infection risk with SGLT2 inhibitors? Why it is still open: The included comparative estimates [7][11][15] use active comparators, and the placebo-anchored meta-analyses [3][9] were excluded by the study-type filter.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 23 Oct 2026 · protocol v0.19